Neuphoria Therapeutics 13D Filing Shows Lynx1 Capital Management LP Boosts Stake To 16.3% And Submits Revised $4.75-Per-Share Buyout Proposal For Neuphoria Therapeutics

Benzinga · 4d ago

- SEC Filing